top of page

Price

chg

chg neg

quotes and stock data may be delayed 15 minutes

 My Notes

Only BPIQ Pro members can create company notes. Learn more here.

52 wk low

low api

52 wk hi

high api

Cash

$179.9M

Burn Rate (Qtr)

$13.5M

Mkt Cap

mkt cap api

Avg Volume

volume api

*cash/burn updated:

Q1 '22

Drug Pipeline

Click the button to see the updated pipeline

No drug found

We don't have any drug data for this company yet

Drug | Disease (links)

Stage (next event)

Catalyst Date

Drug Name

Indication

Phase

Event

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Loading Catalysts...

search in progress

Pipeline powered by

ALT

BPIQ_Logo_RGB-01.jpg

Company Profile

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating treatment for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). P

Recent Posts

See what the community is saying - click to see full post.

EASL 2024 Winners & Losers

EASL 2024 Winners & Losers

Biopharma March Madness Has Begun: Obesity & NASH 😃

COVID-19 Therapeutic Stocks to Watch (June 2021)

COVID-19 Vaccine Stocks To Watch (June 2021)

Big-Mover™ Events June 2021

bottom of page